Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LUNA Trial: Pasireotide LAR and Everolimus in Lung and Thymic Neuroendocrine Carcinoma
2011-002872-17Phase 2Completed
- Sponsor
- Novartis
- Start
- Mar 2013
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 2, randomised trial in Lung neuroendocrine carcinoma (LNEC) and thymic neuroendocrine carcinoma (TNEC) comparing Pasireotide LAR monotherapy, Everolimus monotherapy and Pasireotide LAR + Everolimus combination (3 arms). Primary endpoint: Proportion of patients progression-free at 9 months. Started Mar 2013; status: completed.
02
Drugs
everolimuspasireotide LAR
03
Conditions
Lung neuroendocrine carcinoma (LNEC)thymic neuroendocrine carcinoma (TNEC)
Beyond the preview
Go deeper on 2011-002872-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-002872-17.